Want to see TSE:MSCL full AI Analyst Report?

Satellos Bioscience (MSCL) Price & Analysis

44 Followers

MSCL Stock Chart & Stats

C$13.08

-C$0.65(-4.66%)

At close: Jul 27 4:00 PM EDT

C$13.08

-C$0.65(-4.66%)

Day’s Range― - ―

52-Week RangeC$7.56 - C$18.98

Previous CloseN/A

Volume23.69K

Average Volume (3M)10.88K

Market Cap

C$206.01M

Enterprise ValueC$134.33M

Total Cash (Recent Filing)C$61.74M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Nov 25, 2026

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.14

Shares Outstanding21,216,438

10 Day Avg. Volume11,770

30 Day Avg. Volume10,879

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)4.17

Price to Sales (P/S)0.00

P/FCF Ratio-4.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$34.88

Price Target Upside166.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-3.29

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regenerative Medicine PipelineThe company targets a significant unmet need in skeletal muscle disorders through a focused regenerative-medicine approach. Progress in restoring muscle repair could create differentiated therapeutic value and support a durable commercial opportunity if clinical development succeeds.

Debt-free Balance SheetA debt-free structure reduces solvency risk and avoids mandatory interest or principal payments while the company funds clinical development. Meaningful equity provides a financial cushion and preserves flexibility to allocate capital toward advancing its pipeline.

Recent Cash-flow ModerationAlthough cash generation remains negative, the latest improvement in free cash flow growth suggests spending pressure may be moderating. If sustained, better cash discipline could extend the company’s funding runway and support more efficient clinical execution.

Bears Say

No Revenue GenerationThe absence of revenue means the company has not yet demonstrated commercial traction or internally generated funding for operations. Its financial outlook therefore remains dependent on clinical progress and external capital until a product reaches the market.

Widening Net LossesLosses have expanded materially while revenue remains absent, indicating that development spending is rising faster than the business is producing operating income. Persistent loss expansion can erode equity, reduce funding flexibility, and increase dependence on future financing.

Persistent Cash BurnSubstantial ongoing cash outflows show that reported losses translate into real funding needs rather than being mainly non-cash accounting effects. Continued burn can shorten the available runway and constrain the pace or scale of future clinical development.

Satellos Bioscience News

Satellos management to meet with Cantor

Meeting to be held virtually on October 13 and in Boston on October 14 hosted by Cantor. Published...

15d ago

MSLE

Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data

As previously reported, Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target The...

15d ago

MSLE

Satellos initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target Published first on TheFly...

15d ago

MSLE

Satellos granted composition of matter patent for forazapadin

Satellos (MSLE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled...

18d ago

MSLE

Satellos announces enrollment completed for BASECAMP

Satellos (MSLE) Bioscience announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating...

23d ago

MSLE

Satellos announces U.S. FDA cleared IND application for forazapadin

Satellos (MSLE) Bioscience announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug,...

29d ago

MSLE

Satellos Bioscience to Court Investors at November Healthcare Conferences

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. Satellos Bioscience Inc., a clinical-stage developer of therapies for...

2d ago

MSLE

Satellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin

Satellos Bioscience ( ($TSE:MSCL) ) has shared an update. Satellos Bioscience Inc., a Toronto-based clinical-stage biotech developing small...

18d ago

MSLE

Analyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress

Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on Satellos Bioscience and keeping the price target...

23d ago

MSLE

Satellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular Dystrophy

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience Inc., a Toronto-based clinical-stage biopharmaceutical...

23d ago

MSLE

Satellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $22

Francois Brisebois, an analyst from LifeSci Capital, reiterated the Buy rating on Satellos Bioscience. The associated price target...

29d ago

MSLE

Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding

The latest update is out from Satellos Bioscience ( ($TSE:MSCL) ). Satellos Bioscience has secured U.S. FDA clearance...

29d ago

MSLE

Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress

Satellos Bioscience ( ($TSE:MSCL) ) has provided an announcement. Satellos Bioscience Inc., a Toronto-based clinical-stage biopharmaceutical company listed...

1M ago

MSLE

Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. On September 9, 2026, Satellos Bioscience announced...

1M ago

MSLE

MSCL FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was C$7.56 and its highest was C$18.98 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is C$206.01M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Nov 25, 2026 which is in 33 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on Aug 13, 2026. The company reported -C$0.777 earnings per share for the quarter, missing the consensus estimate of -C$0.725 by -C$0.052.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.85.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 21,216,438 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -C$0.777 in its last earnings report, missing expectations of -C$0.725. Following the earnings report the stock price went down -3.394%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in TSE:MSCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Satellos Bioscience Stock Smart Score

Neutral

Fundamentals

Return on Equity

-72.67%

Trailing 12-Months

Asset Growth

59.96%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.

Satellos Bioscience (MSCL) Earnings & Revenues

Historic Earnings Reports

MSCL Stock 12 Month Forecast

Average Price Target

C$34.88

▲(166.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"C$6","57":"C$57","18.75":"C$18.75","31.5":"C$31.5","44.25":"C$44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.2508,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$56.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.875496000000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$34.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.31286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$25.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.75,31.5,44.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.09,15.486984615384614,18.88396923076923,22.280953846153846,25.67793846153846,29.074923076923074,32.471907692307695,35.868892307692306,39.26587692307692,42.662861538461534,46.05984615384615,49.45683076923076,52.85381538461539,{"y":56.2508,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.09,13.842730461538462,15.595460923076924,17.348191384615387,19.10092184615385,20.853652307692307,22.60638276923077,24.359113230769232,26.111843692307694,27.864574153846156,29.61730461538462,31.37003507692308,33.12276553846154,{"y":34.875496000000005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.09,13.107143076923077,14.124286153846153,15.14142923076923,16.158572307692307,17.175715384615383,18.192858461538464,19.21000153846154,20.227144615384617,21.244287692307694,22.26143076923077,23.278573846153847,24.295716923076924,{"y":25.31286,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.519,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.85,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >